

Tenaxit®

Flupentixol-Melitracen Tablet



Presentation

Tenaxit® Tablet: Each tablet contains Flupentixol Dihydrochloride BP equivalent to Flupentixol 0.5 mg and Melitracen Hydrochloride INN equivalent to Melitracen 10 mg.

Description

Tenaxit consists of two well known and well proven compounds: Flupentixol - a neuroleptic with anxiolytic and antidepressant properties of its own when given in small doses, and Melitracen - a bipolar thymoleptic with activating properties in low doses. In combination the compounds render a preparation with antidepressant, anxiolytic and activating properties.

Maximum serum concentration is reached in about 4 hours after oral administration of Flupentixol and Melitracen. The biological half-life of Flupentixol is about 35 hours and that of Melitracen is about 19 hours. The combination of Flupentixol and Melitracen does not seem to influence the pharmacokinetic properties of the individual compounds.

Indications

Tenaxit is indicated in various types of anxiety, depression and apathy. These include-

- Psychogenic depression
- Depressive neuroses
- Masked depression
- Psychosomatic affections accompanied by anxiety and apathy
- Menopausal depressions
- Dysphoria and depression in alcoholics and drug-addicts

Dosage & administration

Adults: Usually 2 tablets daily: morning and noon.

In severe cases the morning dose may be increased to 2 tablets.

Elderly patients: 1 tablet in the morning.

Maintenance dose: Usually 1 tablet in the morning. In cases of insomnia or severe restlessness additional treatment with sedative in the acute phase is recommended.

Side-effects

In the recommended doses side-effects are rare. These could be transient restlessness and insomnia.

Contraindications

The immediate recovery phase after myocardial infarction. Defects in bundle-branch conduction. Untreated narrow angle glaucoma. Acute alcohol, barbiturate and opiate intoxications. Flupentixol-Melitracen should not be given to patients who have received a MAO-inhibitor within two weeks. Not recommended for excitable or overactive patients since its activating effect may lead to exaggeration of these characteristics.

Precautions

If previously the patient has been treated with tranquilizers with sedative effect these should be withdrawn gradually.

Use during pregnancy and lactation

Flupentixol-Melitracen should preferably not be given during pregnancy and lactation.

Drug interactions

Flupentixol-Melitracen may enhance the response to alcohol, barbiturates and other CNS depressants. Simultaneous administration of MAO-inhibitors may cause hypertensive crises. Neuroleptics and thymoleptics reduce the antihypertensive effect of guanethidine and similar acting compounds and thymoleptics enhance the effects of adrenaline and noradrenaline.

Overdose

Symptoms: In cases of overdosage the symptoms of intoxications by Melitracen, especially anticholinergic nature may dominate. More rarely extrapyramidal symptoms due to Flupentixol occur.

Treatment: Symptomatic and supportive. Gastric lavage should be carried out as soon as possible and Activated Charcoal may be administered. Measures aimed at supporting the respiratory and cardiovascular systems should be instituted. Epinephrine (adrenaline) must not be used for such patients. Convulsions may be treated with Diazepam and extrapyramidal symptoms with Biperiden.

Storage

Do not store above 30 °C. Keep away from light and out of the reach of children.

Commercial pack

Tenaxit® Tablet: Each box contains 5 blister packs of 10 tablets.